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Abstract
Background: Endoplasmic reticulum (ER) calcium storage and release play important roles in B lymphocyte
maturation, survival, antigen-dependent cell activation and immunoglobulin synthesis. Calcium is accumulated
in the endoplasmic reticulum (ER) by Sarco/Endoplasmic Reticulum Calcium ATPases (SERCA enzymes). Because
lymphocyte function is critically dependent on SERCA activity, it is important to understand qualitative and quantitative
changes of SERCA protein expression that occur during B lymphoid differentiation and leukemogenesis.
Methods: In this work we investigated the modulation of SERCA expression during the pharmacologically induced
differentiation of leukemic precursor B lymphoblast cell lines that carry the E2A-PBX1 fusion oncoprotein. Changes
of SERCA levels during differentiation were determined and compared to those of established early B lymphoid
differentiation markers. SERCA expression of the cells was compared to that of mature B cell lines as well,
and the effect of the direct inhibition of SERCA-dependent calcium transport on the differentiation process
was investigated.
Results: We show that E2A-PBX1+ leukemia cells simultaneously express SERCA2 and SERCA3-type calcium
pumps; however, their SERCA3 expression is markedly inferior to that of mature B cells. Activation of protein
kinase C enzymes by phorbol ester leads to phenotypic differentiation of the cells, and this is accompanied
by the induction of SERCA3 expression. Direct pharmacological inhibition of SERCA-dependent calcium transport
during phorbol ester treatment interferes with the differentiation process.
Conclusion: These data show that the calcium pump composition of the ER is concurrent with increased SERCA3
expression during the differentiation of precursor B acute lymphoblastic leukemia cells, that a cross-talk exists between
SERCA function and the control of differentiation, and that SERCA3 may constitute an interesting new marker for the
study of early B cell phenotype.
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Background
Calcium signaling is essential for B lymphocyte responses.
The activation of the B cell antigen receptor and other im-
portant receptors leads, via PLC-γ activation and subse-
quent IP3 production, to the release of calcium
accumulated in the ER via IP3 receptor calcium channels.
ER calcium release, coupled to capacitative calcium influx
from the extracellular space through Orai-type calcium
channels leads to increased cytosolic calcium levels, the
activation of calcineurin and various PKC isoforms and
the activation of NF-κB and NFAT-type transcription fac-
tors that orchestrate B cell activation [1–10].
Calcium-dependent activation is critically dependent
on the function of Sarco/Endoplasmic Reticulum Cal-
cium ATPases (SERCA enzymes). Located in the ER
membrane, SERCA proteins accumulate calcium ions
from the cytosol into the ER lumen by ATP-dependent
active transport, creating a several thousand fold calcium
concentration gradient from the ER (high micromolar)
towards the cytosol (low nanomolar) [11–14]. SERCA
activity is therefore a prerequisite for IP3-induced cal-
cium release to occur [15, 16], and, by recapturing cal-
cium during a calcium release event, SERCA enzymes
also shape the amplitude and the duration of calcium
signals [17], and thus modulate cell activation [18]. Ma-
ture B cells express simultaneously SERCA2b and
SERCA3-type calcium pumps [19, 20]. The calcium af-
finity of SERCA3 is markedly weaker (KCa
2 + ~1.2 μM)
than that of SERCA2b (KCa
2 + ~0.2 μM) [13, 21]. Due to
its lower calcium affinity, SERCA3 will tolerate higher
calcium rises during ER calcium release [13, 21–24]. The
SERCA2b/SERCA3 protein ratio constitutes a unique
mechanism whereby the avidity of the ER for calcium
can be modulated in a cell [25, 26].
Early B cell differentiation proceeds through several
consecutive steps during which an initially immature
lymphoid precursor acquires the cellular machinery re-
quired for the function of the differentiated B cell.
Phenotypic changes that occur during this process, such
as the loss or gain of various markers and gene expres-
sion regulatory networks, have already been described in
considerable detail [27–29]. However, little is known so
far about the functional remodeling of ER calcium
homeostasis and about changes of SERCA-dependent
ER calcium sequestration that may occur during early B
lymphoid differentiation.
Precursor-B ALL cells are blocked at early stages of B-
cell differentiation due to the presence of various genetic
lesions that give rise to different fusion oncoproteins such
as E2A-PBX1 (TCF3-PBX1), BCR-ABL1, MLL-ENL
(KMT2A-MLLT1), TEL-AML1 (ETV6-RUNX1) or others.
These oncoproteins activate distinct molecular oncogenic
mechanisms, influence prognosis, and are widely used for
the molecular classification of precursor-B ALL [30, 31].
In order to investigate SERCA expression during early B
cell differentiation, and to gain insight into its defects in
leukemia, we investigated the effects of protein kinase C
activation by a phorbol ester on the phenotype and SERCA
expression of various precursor B ALL cell lines in vitro.
Phorbol esters activate PKC [32], and are known to induce
differentiation of several myeloid leukemia cell types ac-
companied by increased SERCA3 expression [33, 34]. We
show that the differentiation blockage of E2A-PBX1-
expressing precursor B-ALL cells can be abolished in vitro
by the pharmacological activation of PKC, and that the dif-
ferentiation of these cells is accompanied by marked
changes in SERCA expression. Whereas untreated cells ex-
press simultaneously SERCA2 and SERCA3-type calcium
pumps, the expression of SERCA3, a lower calcium affinity
isoenzyme [13, 21, 24] is preferentially induced upon differ-
entiation, indicating that ER calcium accumulation is func-
tionally remodeled during this process. In addition, we
show that the direct pharmacological inhibition of SERCA-
dependent calcium transport interferes with the differenti-
ation process as detected by CD20 expression.
Methods
Cell culture
Cell lines used in this study were obtained from DSMZ
(Braunschweig, Germany), ATCC (Manassas, VA),
ECACC (Porton Down, UK) or from the originators (see
Additional file 1: Table S1). Authenticity check of cell
lines was performed by short tandem repeat analysis by
the commercial providers. Early passage cells were cul-
tured in suspension in the appropriate culture medium
at 37 °C in humidified cell culture incubators in a 95%
air 5% CO2 atmosphere. Fetal calf serum that supported
vigorous growth of the Kasumi-2 line as single cells
without clumping was selected for culture. Mycoplasma
screening was performed by polymerase chain reaction
using the G238 mycoplasma detection kit of Applied
Biological Materials, Euromedex, Souffelweyersheim,
France. Cell densities and viabilities of exponentially
growing cultures were determined by cell counting using
a Malassez chamber and trypan blue exclusion.
Reagents and treatments
Before treatments cells were centrifuged and suspended
in new complete medium at densities indicated in Fig-
ures and distributed into 60 cm2 plastic Petri dishes.
Non-adherent dishes were used for the various cell lines
because treatment in adherent conditions resulted in the
adherence of a minor fraction (<5%) of the cells follow-
ing treatments, for example for Kasumi-2 cells. Treat-
ment of MHH-CALL3 cells was done in cell culture
grade adherent Petri dishes, since treatment of this cell
line leads to the adherence of the overwhelming majority
(>90%) of viable cells.
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PMA, Gö 6983 and GF 109203X, thapsigargin, cyclo-
piazonic acid and 2,5-di(tert)butyl-1,4-benzohidroqui-
none were obtained from Sigma-Aldrich France, Saint-
Quentin Fallavier, France. Drugs were added to cells
from concentrated stock solutions made in dimethyl-
sulfoxide (DMSO). DMSO vehicle did not exceed 0.01%,
was included in controls and did not interfere with the
experiments.
When PMA treatments were applied in the presence
of Gö 6983 or GF 109203X, these were added to the cell
cultures 30 min before the addition of PMA. PMA and
thapsigargin in double treatment experiments were
added simultaneously. Drugs were thereafter present
during the entire experiment.
Western blotting and flow cytometry
After the appropriate treatments, cells were harvested by
centrifugation and washed with ice cold 150 mM NaCl.
Total cellular protein was then precipitated with 5%
trichloroacetic acid (TCA), centrifuged and dissolved in
modified SDS PAGE lysis buffer. This sample prepar-
ation process, as well as quantification of the protein
content of lysates was performed as described in [35].
Equal amounts of total cellular protein (60 μg/well) were
applied to polyacrylamide gels, and SDS PAGE followed
by immunoblotting onto nitrocellulose was done as pre-
viously described [35]. After electrotransfer, identical
protein loading was checked by Ponceau red staining
and densitometry [35].
Western blotting for SERCA2 and SERCA3 was per-
formed using the IID8 (Sigma-Aldrich, 0.4 μg/ml) and
the PLIM430 mouse monoclonal (10x diluted hybridoma
cell culture supernatant) antibodies, respectively, and
peroxidase-conjugated anti-mouse Ig antibodies as in
[35]. Luminescent signal obtained with the ECL Prime
(Amersham) and SuperSignal West Femto Maximum
Sensitivity (Thermo Fisher) reagents was detected, quan-
tified and analyzed using a BioRad ChemiDoc MP image
acquisition system and the Image Lab 4.0 software. Im-
munoblot signal intensities were normalized to the cor-
responding total protein values as obtained by Ponceau
red staining, and are expressed as fold change in treated
cells versus untreated control.
Detection by Western blotting of CD20 (clone L26
purified mouse monoclonal anti-human CD20cy, Dako
Denmark A/S, 0.2 μg/ml), RAG-1 (Santa Cruz Biotech-
nology, sc-5599, H-300, rabbit polyclonal IgG 0.2 μg/
ml), TdT (clone EPR2976Y, rabbit hybridoma culture
supernatant monoclonal antibody, dilution:3500x, Epi-
tomics), CD19 (clone LE-CD19 purified mouse mono-
clonal anti-human CD19, Thermo Fisher Scientific,
0.33 μg/ml) was performed similarly.
Detection and analysis of expression of various lym-
phoid phenotypic markers (CD3, CD5, CD10, CD19,
CD20, CD22, CD34, CD38, CD45, FMC7, TdT, κ and λ
light chains and IgM) by flow cytometry was done as pre-
viously described [36, 37].
Cytology and immunocytochemistry
Immunocytochemical staining for CD20 expression was
performed on cytologic smears. Suspensions of treated
and untreated control cells of packed cell volume ratio
of approximately 50% were applied to poly-lysine coated
microscopic slides and air-dried overnight. Following fix-
ation in acetone at room temperature for 10 min and
drying the slides were rehydrated and labeled for CD20
expression using the Clone L26 monoclonal mouse anti-
CD20 antibody (Dakocytomation, Les Ulis, France) at a
concentration of 6 μg/ml in Dako REALTM antibody di-
luent (Dakocytomation), using an indirect avidin-biotin-
peroxidase method with 3,3’diaminobenzidine (DAB) as
chromogen on an automated immunostainer (Bench-
mark®, Ventana Medical Systems, Illkirch, France). En-
dogenous peroxidase activity was blocked by treatment
with 3% hydrogen peroxide in phosphate-buffered saline
for 10 min. Incubation with the CD20-specific antibody
was carried out at 37 °C for 30 min, and labeling was re-
vealed using the Ventana iView® DAB Detection kit with
copper enhancement, according to the instructions of
the manufacturer. Slides were counterstained with
hematoxylin and bluing reagent (Ventana). Cells were
photographed using a Zeiss Axio Scope.A1 microscope
and an AxioCam ICc1 camera using the Axiovision 4.8.2
software. May-Grünwald-Giemsa staining of cytological
smears was done using standard methods.
Real time PCR
Following treatments cells were centrifuged, and RNA
was extracted with the RNeasy Mini Kit of Qiagen
(Courtaboeuf, France). RT-PCR was performed on 1 μg
of total RNA using the Iscript cDNA synthesis kit of
Bio-Rad (Marne la Coquette, France) TaqMan gene ex-
pression assays were performed on an ABI prism 7000
apparatus (Applied Biosystems, Courtaboeuf, France)
with the Hs 99999905_m1, Hs 0054487_m1 and Hs
01024558_m1 primer pairs (Applied Biosystems, Life
Technologies, Fisher Scientific, Illkirch, France) for
GAPDH, ATP2A2 (SERCA2) and ATP2A3 (SERCA3),
respectively. Relative gene expression levels after treat-
ments were calculated by the 2-ΔΔCt method normalized
to GAPDH, and expressed as fold change compared to
untreated cells [38].
Statistical analysis
Data are presented as the mean ± SEM, and correspond
to at least three independent experiments. Statistical
analysis was performed using Student’s t test with
GraphPad Prism.
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Results
Induction of SERCA expression in precursor B ALL cells
As investigated in the Kasumi-2 and RCH-ACV cell lines
that carry the t(1;19)(q23;p13) translocation and express
the E2A-PBX1 fusion oncoprotein, PMA treatment led
to enhanced SERCA3 expression. This could be ob-
served from 10−10-10−9 M PMA, and reached a plateau
in the 10−8-10−7 concentration range (Fig. 1a and b). In-
duction of SERCA3 expression was also manifested on
the mRNA level. As shown in Fig. 1c and d, induction of
SERCA3 mRNA expression was observed in both
Kasumi-2 and RCH-ACV cells, already at 12 h of treat-
ments, and this followed a reproducible biphasic pattern
with a 5-6-fold enhancement when compared to un-
treated control. Moreover, the moderate enhancement of
SERCA2 protein expression observed in Kasumi-2 cells
could also be observed on the mRNA level.
Significant induction of SERCA3 protein expression
was observed starting at day 1-2 and reached a plateau
at day 4-5 (Fig. 2a and b). Maximal induction in the cell
lines was approximately five- to sevenfold when com-
pared to untreated cells. DMSO vehicle when applied
alone was without effect. As shown in Fig. 2c and d,
PMA treatment in Kasumi-2 cells led to inhibition of
cell proliferation (Panel C) with maintained viability
(Panel D) up till day 5, whereas longer treatments led to
significant cell death.
SERCA3 expression was induced by PMA in all avail-
able precursor B ALL cell lines bearing the t(1;19)/E2A-
PBX1 translocation. As shown in Fig. 3, the Kasumi-2,
a b
c d
Fig. 1 Induction of SERCA3 expression in precursor B ALL cell lines. Kasumi-2 (a) and RCH-ACV (b) cells were treated by various concentrations of
PMA for 5 days, and SERCA3 (closed columns; 97 kDa) as well as SERCA2 (open columns; 100 kDa) expression was detected by Western immunoblotting
(lower part) and quantified (upper part). Equal total cellular protein loading of blots was checked by Ponceau red staining. PMA treatment led to an
approximately five- or sevenfold increase of SERCA3 expression in Kasumi-2 and RCH-ACV cells, respectively. Concentration-dependent induction of
SERCA expression by PMA could be observed from 10−10-10−9 M and reached a plateau around 10−8-10−7 M, whereas DMSO vehicle was without effect.
c and d: Kasumi-2 and RCH-ACV cells were treated with 10−8 M PMA, and SERCA3 (closed columns), as well as SERCA2 mRNA levels (open columns) were
measured by quantitative RT-PCR and normalized to GAPDH as described in Methods. When compared to untreated cells, SERCA3 mRNA expression
peaked at day 2 of treatment, and a rebound could be observed at day 4
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Fig. 2 Time course of SERCA expression in PMA-treated precursor B ALL cell lines. Kasumi-2 (a) and RCH-ACV (b) cells were treated with 10−7 M
PMA and SERCA3 (closed squares) as well as SERCA2 (open circles) expression was detected by Western blotting (lower part) and quantified (upper part).
Equal protein loading was checked by Ponceau red staining of the membranes. Induction of SERCA3 expression was detected from days 1-2 and
reached a plateau after 4-5 days. Treatment (Kasumi-2 cells, PMA: 10−8 M) led to rapid growth arrest (c) with maintained viability (d) during 5 days
SERCA3
PMA (10-7 M, 5 days) - + - + - +- +- + - +
SERCA2
Ponceau
Fig. 3 SERCA protein expression in various precursor B ALL cell lines. Induction of SERCA3 expression by PMA. Semi-quantitative Western blotting
analysis of SERCA2 and SERCA3 levels in equal amounts of total cellular protein lysates obtained from untreated (-) and PMA-treated (+) cells.
PMA treatment led to enhanced SERCA3 expression in all t(1;19)/E2A-PBX1+ cell lines
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RCH-ACV, LK63, Lila-1, MHH-CALL3 and 697 cell
lines all simultaneously expressed SERCA2 and SERCA3
calcium pump isoforms. When the cells were treated
with 10−7 M PMA for 5 days, the expression of SERCA3
protein was strongly enhanced in all cell lines, whereas
expression of the SERCA2 protein remained unchanged
or was slightly modified in a cell-line dependent manner.
This indicates that the induction of SERCA3 expression
is a universal phenomenon in all E2A-PBX1 expressing
cell lines investigated in this study. On the other hand,
we found that PMA treatment of precursor B ALL cell
lines (Nalm-21, TOM-1, BV173, KOPN-8 and Reh) of
other molecular types (see Additional file 1: Table S1)
led to the death of cultures within 24–48 h.
PMA treatment leads to cell differentiation
The phenotype of Kasumi-2 precursor B ALL cells was
investigated before and after stimulation with 10−7M
PMA for 5 days using established markers of early B cell
differentiation. Whereas before treatment cells expressed
high levels of TdT and RAG-1 and low levels of CD20
proteins, PMA treatment led to strong CD20 expression
and to the simultaneous down-regulation of TdT and
RAG-1 expression (Fig. 4a).
PMA-treatment of cells led to the formation of multi-
cellular aggregates and to morphological changes similar
to a plasmacytoid morphology (Fig. 4b). Whereas un-
treated cells were round, small and displayed high
nucleocytoplasmic ratio and round nuclei, treatment
with 10−8 M PMA for 4 days led to increased cell size,
more abundant, often excentral cytoplasm, lower
nucleocytoplasmic ratio and frequently bilobed nuclei
with clear paranuclear areas.
As studied by flow cytometry, and similarly to previous
observations made on the LK63 and Lila-1 t(1;19) cell
lines [39], untreated Kasumi-2 cells displayed a precur-
sor B lymphoid phenotype (CD3−, CD5−, CD10+, CD19+,
CD20+/-, CD22+, CD34−, CD38+, CD45+, TdT+). As
a b
Fig. 4 Induction of differentiation by PMA in Kasumi-2 cells. a: Cells were treated with 10−7 M PMA during 5 days and the expression of SERCA3,
CD20, TdT, RAG-1 and CD19 was determined by Western blotting daily. Whereas CD19 is expressed in untreated cells, induction of SERCA3 and
CD20 expression by PMA treatment was accompanied by the down-regulation of TdT and RAG-1. b, photographs 1 and 2: PMA treatments led to
the formation of multicellular aggregates. Whereas untreated cells (Photograph 1) grew predominantly as single cells in suspension, PMA treated
cells (10−8 M, 4 days) formed floating multicellular aggregates (Photograph 2; original magnification: 20x; bars: 50 μm). b, photographs 3 and 4:
Induction of CD20 expression in PMA-treated Kasumi-2 cells detected by immunohistochemistry. Cytological smears of untreated (Photograph 3) and
PMA-treated cells (10−8 M, 4 days, photograph 4) were stained for CD20 expression by immunohistochemistry as described in Methods. Brown staining
indicates CD20 expression (original magnification: 40x; bars: 20 μm). b, photographs 5 and 6: May-Grünwald-Giemsa staining of cytological
smears of untreated (photograph 5) and PMA-treated cells (10−8 M, 4 days, photograph 6). PMA treatment led greater cell size, decreased
nucleocytoplasmic ratio (asterisks) and the frequent formation of bilobed, often excentral nuclei (black arrowheads) with a paranuclear halo
(white arrowheads; original magnification: 40x; bars: 20 μm)
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shown in Fig. 5, treatment of cells with 10−8 M PMA for
4 days led to markedly enhanced expression of the
CD19, CD20, CD22 and FMC7 differentiation markers,
whereas the expression of markers of immaturity such
as CD10 or TdT was decreased. PMA treatment, how-
ever, did not lead to κ or λ chain or IgM expression (not
shown), indicating however, that the cells do not attain a
mature B cell phenotype.
Induction of SERCA3 expression is PKC-dependent
The induction of SERCA3 expression by PMA was
investigated in the presence or absence of pharmaco-
logical inhibitors of PKC. As shown in Fig. 6, when
cells were preincubated with Gö 6983 or with GF
109203X for 30 min, the consecutive addition of 10−8
M PMA (a maximally active concentration) was with-
out effect on SERCA expression, indicating the in-
volvement of conventional or novel-type PKC activity
in PMA-induced SERCA expression.
Comparison of SERCA3 expression in precursor B and
mature B cell lines
In order to further correlate SERCA3 expression with
the state of differentiation of neoplastic B cells, SERCA3
expression of precursor B cell lines was compared to
that of an extensive set of randomly selected mature B
cell lines (see Additional file 1: Table S1). As shown in
Fig. 7, SERCA3 expression in all individual precursor B
cell lines was weaker than in any of the investigated ma-
ture cell lines. A highly significant, on average 15-fold
higher SERCA3 expression could be observed in mature
B cell lines when compared with the average expression
in the precursor B cell group.
SERCA activity is involved in the control of cell
differentiation
The role of SERCA function in the differentiation of
leukemic B cells was investigated using thapsigargin, a
high affinity, selective inhibitor of SERCA-dependent
calcium transport [40]. As shown in Fig. 8, Treatment of
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CD19 CD20
CD22 FMC7 TdT
c
Fig. 5 Flow cytometric analysis of phenotypic changes induced by PMA treatment. Kasumi-2 cells were treated with 10−8 M PMA for 4 days
(black curves) and the expression of various early B lymphoid phenotypic markers was compared to untreated cells (grey curves). Appropriate
isotype-matched irrelevant antibodies were used as negative control (light grey curves). Treatment led to increased expression of the CD19, CD20,
CD22 and FMC7 differentiation markers (b, c, d and e, respectively), whereas the expression of the CD10 (a) and of intracellular TdT (f) decreased
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Kasumi-2 cells with sub-nanomolar concentrations of
thapsigargin completely abolished the induction of
CD20 expression induced by PMA (Fig. 8a). Inhibition
of PMA-induced CD20 expression by thapsigargin was
observed in the absence of significant toxicity during the
experiments (Fig. 8b), although higher thapsigargin con-
centrations were, in accordance with the literature [41],
toxic. Similar observations were made with cyclopiazonic
acid or 2,5-di-tert-butyl-1,4-benzohydroquinone, two
other, structurally unrelated SERCA inhibitors as well
(data not shown).
Discussion
We show for the first time that ER calcium pump ex-
pression is remodeled during early B lymphoid differen-
tiation. Activation of PKC-dependent signaling with a
phorbol ester-type DAG analog in the Kasumi-2 B ALL
cell line, blocked at the precursor B stage, led to the in-
duction of differentiation of the cells as detected by the
loss or decrease of expression of CD10, TdT and RAG-1
and the induction of expression of the CD19, CD20,
CD22 and FMC7 markers, as well as morphological
changes. This process was accompanied by a marked in-
duction of the expression of SERCA3 mRNA and pro-
tein, whereas the expression of SERCA2 was only
moderately increased. SERCA3 induction was observed
on the protein, as well as the mRNA level. Whereas
SERCA3 protein induction reached a plateau, mRNA in-
duction followed a biphasic pattern. This may be due
the dynamic interplay of various regulatory mechanisms,
these, however, remain to be identified.
The induction of SERCA3 expression upon PMA
treatment was observed in all B ALL cell lines investi-
gated that carry the t(1;19) translocation giving rise to
the E2A-PBX1 fusion oncoprotein, whereas in cell lines
that belong to other molecular types such as t(9;22),
t(11;19) or t(12;21) that express the BCR-ABL, MLL-
ENL or TEL-AML1 fusion oncoproteins, respectively,
we observed that PMA treatment in the same conditions
led to rapid cell death. This suggests that the E2A-PBX1
expressing B ALL may constitute a molecular subtype in
which differentiation blockage can be overcome by PKC
activation. This may help to better understand the mo-
lecular mechanisms responsible for the inhibition of
differentiation of this type of leukemia, should be inves-
tigated on primary leukemic cells ex vivo, and may be of
potential importance for the development of targeted
therapies in the future.
In addition to activating protein kinase C (PKC) isoen-
zymes belonging to the conventional and novel subfam-
ilies, PMA can bind to and activate other DAG-binding
proteins [42–47], including the RasGRP1 guanine nu-
cleotide exchange factor [48]. However, the inhibition of
the effects of PMA on the expression of SERCA3 and of
other differentiation markers by PKC inhibitors indicates
that PKC activation is the essential initiating step of the
pharmacologically induced differentiation process that
leads to the induction of SERCA3 expression in E2A-
PBX1-expressing t(1;19) precursor B ALL cells. The pre-
cise identification of the PKC isoforms involved will
require further studies such as, for example, PKC
isoform-specific knock-down or gene invalidation.
Strong SERCA3 expression has already been observed
in normal mature resting B lymphocytes in situ in lymph
node follicles [20], and an approximately fivefold increase
of SERCA3 mRNA levels can be seen in the ImmGen
database [49] when pro- and pre-B cell populations and
newly formed B cells are compared (see Additional file 2:
Figure S1 and and Additional file 3 Figure: S2 for the ex-
pression profile of SERCA3, SERCA2 and various estab-
lished differentiation markers, respectively), suggesting
that enhanced SERCA3 expression occurs during normal
B lymphocyte differentiation. The investigation of the
cross-talk between key B cell differentiation regulatory
mechanisms and SERCA function during in vitro differen-
tiation of normal B lymphocyte precursors will help to
better understand the underlying regulatory mechanisms,
as well as the role of ER calcium homeostasis in B
lymphocyte maturation.
SERCA3
SERCA2
CD20
TdT
RAG-1
Gö 6983 (10-6 M)
GF 109203X (10-6 M)
PMA (10-8 M) - + + - + -
- +- + -
- - - - + +
-
1 2 3 4 5 6
Ponceau
Fig. 6 Effect of PKC inhibitors on PMA-induced cell differentiation.
Kasumi-2 cells were treated with 10−8 M PMA in the presence or the
absence of the Gö 6983 or the GF 109203X PKC inhibitor for 4 days,
and the expression of SERCA3 and SERCA2, as well as of CD20, TdT
and RAG-1 proteins was detected by Western blotting as described
in Methods. Equal loading was controlled by Ponceau red staining.
When compared to untreated cells (lane 1), PMA treatment alone
(lane 2) led to the induction of SERCA3 and CD20 expression and
the down-regulation of TdT and RAG-1 proteins. Gö 6983 or GF
109203X abolished the effects of PMA (lanes 3 and 4). When applied
alone, Gö 6983 or GF 109203X had no significant effect of the cells
(lanes 5 and 6)
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Our work indicates that E2A-PBX1-transformed B-
ALL cells can be induced to differentiate by PKC activa-
tion, and that induction of SERCA3 mRNA and protein
expression is induced during this process. A sharp con-
trast could also be observed when SERCA3 expression
of precursor B ALL cell lines was compared to a large
set of cell lines encompassing a wide range of mature B
neoplasia types. Despite variation among different cell
lines, SERCA3 expression was several-fold higher in ma-
ture cells when compared to precursor B cell lines. This
indicates that systematic differences exist in terms of
SERCA3 expression between immature and mature B
lymphoid malignancies, and that SERCA3 may therefore
constitute a useful new phenotypic marker for the study
of B lymphoid differentiation and leukemia/lymphoma
phenotype analysis.
Calcium signaling plays an important role in the acti-
vation of mature B cells [5, 50]. Antigen binding to the
BCR leads to phospholipase-C activation, IP3 production
and calcium release from IP3-sensitive intracellular
pools [50–52]. The calcium affinity of SERCA3 is infer-
ior when compared to the simultaneously expressed
SERCA2 isoform [21; 23], and SERCA3 has been shown
to be preferentially associated with the IP3-sensitive
intracellular calcium compartment in platelets [53]. It is
therefore tempting to hypothesize that the induction of
SERCA3 expression during the maturation of B cell pre-
cursors is part of the differentiation program, whereby
the cells acquire an intracellular calcium storage com-
partment poised to mount larger calcium release signals
upon BCR activation.
When cell differentiation was conducted in the presence
of sub-nanomolar, non-toxic concentrations of thapsigar-
gin, a high affinity pan-SERCA inhibitor, induction of
CD20 expression by PMA was completely suppressed.
Similar results were obtained by using cyclopiazonic acid
and 2,5-di(tert)butyl-1,4-benzohidroquinone, two other,
structurally unrelated SERCA inhibitors as well. These ob-
servations show, that SERCA function is required for dif-
ferentiation to proceed, and that the perturbation of
SERCA activity can interfere with this process. The identi-
fication of the relative contribution of SERCA3 and
SERCA2 to cell differentiation will require further studies
based on the direct, selective modulation of SERCA3 and
SERCA2 levels. This can be accomplished by isoenzyme-
specific transgene overexpression, gene invalidation or
knock-down techniques. When applied in conjunction
with genetically engineered fluorescent calcium indicators
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levels of SERCA3. When SERCA3 expression is compared between pre-B and mature B cells as a group, an approximately fifteen fold higher expression is
observed in mature B cells in a highly significant manner (p = 0.0087)
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(GECIs) targeted to the ER lumen or the cytosol, these
studies will allow to better understand the functional
cross-talk that occurs between ER calcium homeostasis
and the control of cell differentiation and its defects in
leukemia.
Conclusions
In summary, this work shows, for the first time that
SERCA3 expression is induced during early B cell differ-
entiation, inhibition of SERCA3 expression and the dif-
ferentiation block in pre-B ALL cells can be overcome
by PKC activation, and that unperturbed SERCA func-
tion is required for cell differentiation. In addition, these
data indicate that SERCA3 may serve as a useful new
phenotypic marker for the study of B cell differentiation
and its defects in leukemia.
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